SYBX - Synlogic, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
7.64
+0.10 (+1.33%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close7.54
Open7.44
Bid7.25 x 1000
Ask9.10 x 800
Day's Range7.44 - 8.04
52 Week Range7.20 - 15.00
Volume92,710
Avg. Volume118,269
Market Cap194.42M
Beta (3Y Monthly)2.70
PE Ratio (TTM)N/A
EPS (TTM)-2.24
Earnings DateNov 12, 2018 - Nov 16, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est19.33
Trade prices are not sourced from all markets
  • Business Wire4 days ago

    Synlogic Expands Capabilities in Manufacturing with the Appointment of Head of Technical Operations and Establishment of In-house Production of Clinical Trial Material for its Synthetic BioticTM Medicines

    Synlogic, Inc. (SYBX), a clinical-stage drug discovery and development company applying synthetic biology to beneficial microbes to develop novel living medicines, today announced the appointment of Antoine Awad as Head of Technical Operations, and the expansion of its manufacturing capabilities to produce clinical trial material for mid-stage studies of its oral and immuno-oncology programs, through entry into an agreement to lease GMP clean-room space from the Azzur Group, LLC. “We are delighted to welcome Tony to Synlogic at this critical stage in the Company’s development as we expand our manufacturing capabilities enabling the production of high-quality, clinical trial material in-house,” said Aoife Brennan, M.B., Ch.

  • GlobeNewswire23 days ago

    Research Report Identifies Synlogic, Consolidated Water Co., AeroCentury, Tecogen, Truett-Hurst, and Marchex with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

    NEW YORK, Nov. 23, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Business Wire25 days ago

    Synlogic to Webcast Presentation at the 30th Annual Piper Jaffray Healthcare Conference

    Synlogic (SYBX) announced today that Aoife Brennan, M.B., B.Ch., Synlogic’s president and chief executive officer, will provide a corporate update at the 30th Annual Piper Jaffray Healthcare Conference at 8:30 am ET on Wednesday, November 28, 2018, in New York City. Synlogic is pioneering the development of a novel class of living medicines, Synthetic Biotic medicines, based on its proprietary drug development platform. Synlogic leverages the tools and principles of synthetic biology to genetically engineer beneficial microbes to perform or deliver critical functions missing or damaged due to disease.

  • Business Wirelast month

    Synlogic Reports Third Quarter 2018 Financial Results and Provides Program Updates

    – Advancement of SYNB1891, the first Synthetic Biotic™ immuno-oncology candidate to enable Investigational New Drug Application filing in 2H 2019 –

  • Business Wirelast month

    Synlogic Presents Data at the 2018 Liver Meeting, the Annual Meeting of the American Association for the Study of Liver Disease (AASLD)

    Synlogic, Inc. (SYBX), a clinical-stage drug discovery and development company applying synthetic biology to beneficial microbes to develop novel living medicines, today announced the presentation of data from a cross-sectional study on ammonia levels in patients with cirrhosis and healthy volunteers, and preclinical studies of its Synthetic Biotic strains in rodent models of liver failure. The presentations were made at The Liver Meeting, the annual meeting of the American Association for the Study of Liver Disease (AASLD), which is being held in San Francisco, November 9 to 13, 2018. “Hepatic Encephalopathy is a major cause of morbidity and mortality in patients with chronic liver disease.

  • Business Wirelast month

    Synlogic Announces Third Quarter 2018 Conference Call and Webcast

    Synlogic, Inc. (Nasdaq: SYBX), announced today that the Company will release its third quarter 2018 financial results after the market closes on Tuesday, November 13, 2018. The conference call dial-in numbers are (844) 815-2882 for domestic callers and (213) 660-0926 for international callers. Synlogic is pioneering the development of a novel class of living medicines, Synthetic Biotic medicines, based on its proprietary drug development platform.

  • Business Wirelast month

    Synlogic Presents Preclinical Data from First Synthetic BioticTM Clinical Candidate in Immuno-Oncology at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting

    Synlogic, Inc. (SYBX), a clinical-stage drug discovery and development company applying synthetic biology to beneficial microbes to develop novel living medicines, today announced the presentation of preclinical data from its first immuno-oncology (IO) program at the 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018). Synlogic’s first Synthetic Biotic clinical candidate (SYNB1891) is designed to induce the production of type I interferon (IFN) through dual activation of innate immune pathways. Data that will be presented at SITC 2018 demonstrate that SYNB1891 generated significant anti-tumor activity, systemic immunity and long-term immunological memory in mouse tumor models.

  • Will Synlogic, Inc (SYBX) Report Negative Earnings Next Week? What You Should Know
    Zackslast month

    Will Synlogic, Inc (SYBX) Report Negative Earnings Next Week? What You Should Know

    Synlogic, Inc (SYBX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Business Wirelast month

    Synlogic to Host Analyst & Investor Event at the Society for Immunotherapy of Cancer (SITC) 2018 Annual Meeting

    Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company applying synthetic biology to probiotics to develop novel, living medicines, today announced that the Company will host an event for analysts and investors in conjunction with the Society for Immunotherapy of Cancer’s 33rd Annual Meeting * Pre-Conference Programs (SITC 2018), with formal presentations beginning at 12:30 pm ET on November 10, 2018. At SITC 2018, Synlogic will deliver a poster presentation of preclinical data for its innate immune activator candidate.

  • Business Wire2 months ago

    Synlogic Appoints Dr. Aoife Brennan as President and Chief Executive Officer

    Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company applying synthetic biology to probiotics to develop novel, living medicines, today announced the appointment of Aoife Brennan, M.B., B.Ch., as president and chief executive officer of Synlogic, effective immediately. Dr. Brennan joined Synlogic as chief medical officer in 2016 and has served as interim president and chief executive officer since May 2018. “After conducting a thorough search process, it was clear to the board of directors that Aoife is the right person to lead Synlogic at this time in the company’s evolution,” said Peter Barrett, chairman of Synlogic’s board of directors.

  • Business Wire3 months ago

    Synlogic to Webcast Presentation at the Leerink Partners Roundtable Series: Rare Disease & Oncology

    Synlogic (SYBX) announced today that Aoife Brennan, M.B., B.Ch., Synlogic’s interim president and chief executive officer, and chief medical officer, will present a corporate update at the Leerink Partners Roundtable Series on Rare Diseases and Oncology at 11:30 am ET on Tuesday, October 2, 2018, in New York City. Synlogic is pioneering the development of a novel class of living medicines, Synthetic Biotic medicines, based on its proprietary drug development platform.

  • Business Wire3 months ago

    Ra Pharma Elects Aoife M. Brennan, M.B., B.Ch., to Board of Directors

    Ra Pharmaceuticals, Inc. (RARX) today announced the election of Aoife M. Brennan, M.B., B.Ch., to its board of directors. “Dr. Brennan has an impressive track record of success in advancing the development of numerous drug candidates throughout her career, with experience in the fields of rare disease, hematology, and neurology, among other key therapeutic areas,” said Doug Treco, PhD, President and Chief Executive Officer of Ra Pharma. Dr. Brennan joined Synlogic in 2016 from Biogen, where she most recently served as Vice President and Head of the Rare Disease Innovation Unit, which included programs ranging from pre-clinical to commercial.

  • Investor's Business Daily3 months ago

    How This Biotech IPO Is Facing Off Vs. BioMarin In Metabolic Disease

    Rubius Therapeutics could rival BioMarin Pharmaceutical in treating a metabolic disorder but, first, the duo will face a dark horse candidate in the form of Synlogic.

  • Business Wire3 months ago

    Synlogic Reports Positive Interim Phase 1/2a Data Demonstrating Safety, Tolerability and Proof-of-Mechanism in Healthy Volunteers for SYNB1618, in Development for the Management of Phenylketonuria (PKU)

    Synlogic, Inc., (Nasdaq:SYBX) a clinical stage company applying synthetic biology to probiotics to develop novel, living medicines, today announced positive interim clinical data from the healthy volunteer (HV) arm of its ongoing Phase 1/2a study of SYNB1618 in HVs and patients with PKU. The first part of this trial, which evaluated SYNB1618 versus placebo (PBO) in single- (SAD) and multiple-ascending dose (MAD) cohorts of HVs, successfully met the study’s primary objectives, to demonstrate safety and tolerability of SYNB1618 in HVs and to identify a suitable dose to evaluate in patients with PKU.

  • Business Wire4 months ago

    Synlogic to Webcast Presentation at the H. C. Wainwright 20th Annual Global Investment Conference

    Synlogic (SYBX) announced today that Aoife Brennan, M.B., B.Ch., Synlogic’s interim president and chief executive officer, and chief medical officer, will present a corporate update at the H. C. Wainwright 20th Annual Global Investment Conference at 8:45 am ET on Wednesday, September 5, 2018, in New York City. Synlogic is pioneering the development of a novel class of living medicines, Synthetic Biotic medicines, based on its proprietary drug development platform.

  • Business Wire4 months ago

    Synlogic Publishes Preclinical Data Supporting Development of SYNB1618, a Synthetic Biotic™ Medicine as a Potential Treatment for Phenylketonuria

    Synlogic, Inc., (SYBX) a clinical stage company applying synthetic biology to probiotics to develop novel, living medicines, today announced the publication of data from preclinical studies of SYNB1618, the Company’s Synthetic Biotic development program targeting PKU, in Nature Biotechnology. The data demonstrate that oral administration of SYNB1618 significantly reduced blood phenylalanine (Phe) levels, the key metabolite associated with PKU, in mouse models of PKU and resulted in dose-dependent pharmacodynamics in healthy non-human primates (NHPs).

  • Business Wire4 months ago

    Synlogic Reports Second Quarter 2018 Financial Results and Provides Program Updates

    - Data from Phase 1/2 studies of SYNB1618 and SYNB1020 expected by end of 2018 –

  • Business Wire4 months ago

    Synlogic to Webcast Presentation at the 2018 Wedbush PacGrow Healthcare Conference

    Synlogic (SYBX) announced today that Aoife Brennan, M.B., B.Ch., Synlogic’s interim president and chief executive officer, and chief medical officer, will present a corporate update at the 2018 Wedbush PacGrow Healthcare Conference at 3:05pm ET on Tuesday, August 14, 2018, in New York City. Synlogic is pioneering the development of a novel class of living medicines, Synthetic Biotic medicines, based on its proprietary drug development platform.

  • Business Wire6 months ago

    Synlogic Presents New Preclinical Data from Synthetic Biotic™ Immuno-Oncology Program at FOCIS 2018

    Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage drug discovery and development company applying synthetic biology to probiotics to develop novel living medicines, announced the presentation of new preclinical data from its Synthetic Biotic medicine oncology program at the annual meeting of the Federation of Clinical Immunology Societies (FOCIS 2018) held June 20-23, in San Francisco, CA. The data demonstrate the breadth of the company’s platform to generate Synthetic Biotic medicines that secrete or consume immunologically relevant compounds for the potential treatment of cancer and inflammation. “These data highlight the plasticity of our Synthetic Biotic platform and its potential as a robust engine for the production and delivery of a variety of immunological payloads, which can have a profound effect on the tumor microenvironment and potential therapeutic use in immune-related conditions,” said Jose Lora, Ph.D., Synlogic’s vice president of research.

  • Business Wire6 months ago

    Synlogic Joins Russell 3000® Index

    Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company applying synthetic biology to probiotics to develop novel, living medicines, today announced the company’s addition to the Russell 3000® Index, following the Russell US Indices’ annual reconstitution, effective Monday, June 25, 2018. “We are pleased to benchmark Synlogic’s growth with our addition to the Russell 3000 Index, which offers a platform to increase the company’s visibility and exposure to leading institutional investors,” said Aoife Brennan, M.B., B.Ch., Synlogic’s interim president and chief executive officer and chief medical officer. Membership in the Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index as well as the appropriate growth and value style indices.

  • Business Wire6 months ago

    Synlogic Presents Preclinical Data from Synthetic BioticTM Medicine, SYNB1618, for the Treatment of Phenylketonuria

    Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage drug discovery and development company applying synthetic biology to probiotics to develop novel living medicines, today announced the presentation of preclinical data from SYNB1618, an investigational Synthetic Biotic medicine currently being evaluated in an ongoing Phase 1/2a clinical trial in healthy volunteers and patients with PKU. The data demonstrate that oral administration of SYNB1618 resulted in lower blood Phe levels and a quantitative, dose-dependent production of biomarkers indicating SYNB1618-related activity in an animal model of PKU and healthy NHPs. “For patients with PKU, life-long disease management can be challenging due to the protein-restricted diet required to accompany currently available treatments.

  • Why Synlogic (SYBX) Could Be a Potential Winner
    Zacks6 months ago

    Why Synlogic (SYBX) Could Be a Potential Winner

    Synlogic (SYBX) sees solid earnings estimate revisions and looks poised to shock the market, and yet seems overlooked by the investors.

  • Business Wire6 months ago

    Synlogic Presents New Preclinical Data from Synthetic Biotic™ Medicine, SYNB1020, Highlighting Beneficial Activity in Animal Model of Liver Disease at Digestive Disease Week®

    Synlogic, Inc.  , a clinical-stage drug discovery and development company applying synthetic biology to probiotics to develop novel living medicines, announced that new preclinical data from SYNB1020, a Synthetic Biotic medicine currently being evaluated in an ongoing Phase 1b/2a clinical trial in patients with cirrhosis and elevated ammonia, were presented at Digestive Disease Week , held June 2-5, ...

  • Synlogic (SYBX) Enters Oversold Territory
    Zacks7 months ago

    Synlogic (SYBX) Enters Oversold Territory

    Synlogic, Inc. (SYBX) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock